This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Doidge, N. Articles by Mosher, P. Search for Related Content PubMed PubMed Citation Articles by Doidge, N. Articles by Mosher, P. Social Bookmarking                   What's this?

Psychoanalytic Patients in the U.S., Canada, and Australia: I. DSM-III-R Disorders, Indications, Previous Treatment, Medications, and Length of Treatment

Canadian Institute of Psychoanalysis, Toronto Branch, 180 Bloor Street West (501) Toronto, Ontario, M5S 2V6 CANADA, Columbia University Center for Psychoanalytic Training and Research, Long-term Psychotherapy, Psychotherapy Program, Department of Psychiatry, University of Toronto, Norman.doidge{at}utoronto.ca

Barry Simon

Department of Psychiatry, University of Toronto

Lee Brauer

American Psychoanalytic Association

Donald C. Grant

Australian Psychoanalytical Society

Michael First

Biometrics Research Department, New York State Psychiatric Institute, Columbia University

Jacqueline Brunshaw

Clinical Psychology Program, York University, Toronto

William J. Lancee

Department of Psychiatry, Mount Sinai Hospital, Department of Psychiatry, University of Toronto

Annette Stevens

Division of Community Mental Health, Department of Psychiatry, University of British Columbia

John M. Oldham

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina

Paul Mosher

Psychoanalytic Electronic Publishing

To determine the demographics, DSM-III-R disorders diagnosed, indications used in recommending psychoanalysis, previous treatment histories, use of medication, and length of treatment in patients in psychoanalysis in the U.S., Canada, and Australia, a mail survey of practice was sent to every other active member of the American Psychoanalytic Association and every member of the Australian Psychoanalytical Society. This supplemented an earlier survey sent to all Ontario psychoanalysts. The response rates were 40.1 % (n=342) for the U.S., 67.2% (n=117) for Canada, and 73.9% (n=51) for Australia. Respondents supplied data on 1,718 patients. The employment rate for patients increases as analysis progresses (p < .0001). The mean number of concurrent categories of disorders (Axis I, Axis II, and Disorders First Evident in Childhood) per patient at the start of treatment is 5.01 (SD=3.66; median=4; mode=3). There are no statistically significant differences across countries. Mood, anxiety, sexual dysfunction, and personality disorders are most common. American Psychiatric Association / American Psychoanalytic Association peer review criteria for indicating psychoanalysis are followed for 86.5% of patients. Over 80% of patients in all three countries had undergone previous treatments prior to analysis. In the U.S., 18.2% of analysands are on concurrent psychoactive medication; in Australia, 9.6%. The mean length of analyses conducted in the U.S. is 5.7 years, in Australia 6.6, and in Canada 4.8. Psychoanalytic patients in all three countries have similar rates of DSM-III-R psychopathology, and many indications of chronicity.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?